1. Home
  2. CELU vs EVAX Comparison

CELU vs EVAX Comparison

Compare CELU & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.27

Market Cap

34.5M

Sector

Health Care

ML Signal

N/A

EVAX

Evaxion Biotech

HOLD

Current Price

$3.98

Market Cap

33.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELU
EVAX
Founded
2016
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.5M
33.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CELU
EVAX
Price
$1.27
$3.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$6.00
$12.33
AVG Volume (30 Days)
54.7K
68.2K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,578,000.00
$7,650,000.00
Revenue This Year
N/A
$128.77
Revenue Next Year
$76.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.17
52 Week Low
$1.00
$1.20
52 Week High
$4.35
$12.15

Technical Indicators

Market Signals
Indicator
CELU
EVAX
Relative Strength Index (RSI) 42.00 34.64
Support Level $1.25 $3.88
Resistance Level $1.32 $4.85
Average True Range (ATR) 0.08 0.36
MACD 0.02 -0.09
Stochastic Oscillator 34.37 8.13

Price Performance

Historical Comparison
CELU
EVAX

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Share on Social Networks: